Abstract |
Compared with beta-lactam antibiotics, rifampin releases smaller quantities of proinflammatory cell wall products from Streptococcus pneumoniae in vitro. Mice infected intracerebrally with S. pneumoniae were treated subcutaneously with 2-mg doses of rifampin or ceftriaxone (n=43 each) every 12 h for 3 days and then observed for another 3 days. Rifampin reduced overall mortality from 49% to 26% (P=.04). Kaplan-Meyer analysis revealed a substantial reduction of mortality during the first 24 h in mice receiving rifampin (difference in survival time: P=.007). Eight h after receiving a single 2-mg dose of rifampin or ceftriaxone, rifampin-treated mice had lower serum and cerebrospinal fluid concentrations of lipoteichoic and teichoic acids than did ceftriaxone-treated mice (median serum level: <0.5 vs. 27.0 ng/mL, P=.02; median cerebrospinal fluid level of pooled specimens: 97.5 vs. 206.0 ng/mL). Thus, the use of rifampin appears promising for reducing the release of proinflammatory bacterial components and decreasing early mortality in bacterial meningitis.
|
Authors | R Nau, A Wellmer, A Soto, K Koch, O Schneider, H Schmidt, J Gerber, U Michel, W Brück |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 179
Issue 6
Pg. 1557-60
(Jun 1999)
ISSN: 0022-1899 [Print] United States |
PMID | 10228082
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Inflammation Mediators
- Ceftriaxone
- Rifampin
|
Topics |
- Animals
- Ceftriaxone
(therapeutic use)
- Inflammation Mediators
- Meningitis, Pneumococcal
(drug therapy, immunology, mortality)
- Mice
- Mice, Inbred C57BL
- Probability
- Rifampin
(therapeutic use)
|